Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | AGER | Q15109 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209132 | 1.00 | ADORA2A (0.44) | ADORA2AADORA1FGFR1FGFR4LMNA | |
| SCHEMBL6176934 | 0.79 | ADORA2A (0.43) | ADORA2AADORA1LMNASMN1; SMN2 | |
| SCHEMBL6177911 | 0.75 | MEN1 (0.49) | ADORA2AADORA1LMNASMN1; SMN2KDM4E | |
| SCHEMBL31720305 | 0.73 | FGFR1 (0.42) | FGFR1FGFR4LMNASMN1; SMN2GAA | |
| SCHEMBL6177173 | 0.73 | POLB (0.45) | ADORA2AADORA1LMNASMN1; SMN2APAF1 | |
| SCHEMBL6286371 | 0.73 | POLB (0.45) | ADORA2AADORA1LMNASMN1; SMN2APAF1 | |
| SCHEMBL7726895 | 0.72 | CDK2 (0.41) | ADORA2AADORA1KDM4EMAPTPOLB | |
| SCHEMBL18226830 | 0.71 | GABRG2 (0.41) | FGFR1FGFR4LMNAMAPK14HTT | |
| SCHEMBL7863634 | 0.70 | FGFR1 (0.40) | ADORA2AFGFR1FGFR4LMNASMN1; SMN2 | |
| SCHEMBL31599667 | 0.70 | FGFR1 (0.41) | FGFR1FGFR4SMN1; SMN2MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392280-A4 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | ADORA2A 4495/4885ADORA1 3559/4885FGFR1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.